Skip to main content
American Journal of Preventive Cardiology logoLink to American Journal of Preventive Cardiology
editorial
. 2026 Sep 18;30:101835. doi: 10.1016/j.ajpc.2026.101835

Examining patient-level factors associated with statin initiation: Applying the smallest worthwhile difference to the art of shared decision making

Eve Manghis a, Ramzi Dudum b,⁎
PMCID: PMC13740849  PMID: 42997052

Statins are a well-established, generic, and cost-effective tool for curbing the morbidity and mortality associated with atherosclerotic cardiovascular disease (ASCVD) and are recommended in many primary prevention scenarios [1,2] Despite broad evidence and guideline recommendations for statin use in primary prevention, adoption remains suboptimal [3].

While effective primary prevention begins with accurate ASCVD risk assessment, treatment decisions are largely made through shared decision-making (SDM), which incorporates a patient’s values, priorities, and risk perceptions. This requires clinicians to adequately communicate both a patient’s risk for an ASCVD event and the risks and benefits of interventions to lower this risk. Understanding the key features that influence patient decision-making is essential to refining communication in SDM and improving patient initiation of preventive therapies when indicated.

In this issue of The American Journal of Preventive Cardiology, Luo and colleagues build upon their prior work examining the smallest worthwhile difference (SWD) for statin therapy to better understand patient treatment preferences [4] SWD is the minimum absolute risk reduction in cardiovascular events at which participants would consider initiating statins, given potential trade-offs. The authors previously found that, among adults aged 40 to 75 without prior statin use, roughly 1 in 4 US participants and 1 in 3 Japanese participants expressed unwillingness to initiate statin therapy in a theoretical high-risk (20% 10-year risk) scenario. The primary analysis suggested that participants required an SWD ≥50% above the expected benefit of statins in the highest risk scenario, underscoring a desire for greater benefits than statins typically provide.

In this study, Luo and colleagues performed a secondary analysis of survey data from the US and Japan to examine the correlates of SWD variation for statin use across three prespecified 10-year ASCVD risk scenarios [5] Participants reviewed standardized information about statin therapy and were presented with three ASCVD risk scenarios in random order (low risk—2%, intermediate risk—10%, and high risk—20%). In these scenarios, participants answered a series of iterative questions about their willingness to initiate a statin if doing so would lower their risk by a specified percentage.

Among 40–75-year-old participants, the majority were statin-naive (US—62.1%; Japan—83.9%). In both groups, numerous factors were associated with a lower SWD, indicating increased openness to statin therapy, including ASCVD history, hypercholesterolemia, prior education on blood cholesterol, current statin use, and moderate-to-high self-perceived risk. No single variable could discriminate or predict SWD levels. Lastly, in adjusted analyses, patients who received cholesterol education were less likely to select a higher SWD, indicating a greater willingness to initiate statin therapy [5].

These findings mirror clinical practice, where SDM reveals significant variation in how patients prioritize and incorporate individual variables for treatment decisions. They suggest that providers might rely on a multipronged approach, recognizing that certain factors might resonate more or less for each patient.

When presented with any of the three ASCVD risk scenarios, participants with low perceived ASCVD risk were less likely to accept a statin than those with a moderate or high perceived risk [5] Interest in statins has been shown to increase after patients at high ASCVD risk review their own risk and harm data [6] This provides a reflective opportunity to interrogate how best to convey actual risk information to those at higher risk.

The 2026 American College of Cardiology/American Heart Association Dyslipidemia guidelines provide an opportunity to better individualize ASCVD risk stratification using the “Classify, Personalize, Reclassify” framework, utilizing an expanded toolkit to help patients better understand their ASCVD risk [1] Personalization involves considering risk enhancers that may not be captured by population-based classification tools, such as family history of ASCVD, high-risk ancestry, and elevated biomarkers such as lipoprotein(a).

A final risk estimate can be further enhanced by select testing, such as coronary artery calcium (CAC) scoring, which provides a powerful visualization of subclinical atherosclerosis. CAC has been shown to significantly increase the likelihood of initiating lipid-lowering medication and adopting lifestyle modifications, and a CAC-informed primary prevention strategy has been shown to reduce lipid levels and slow plaque progression on coronary computed tomography angiography among intermediate-risk individuals [7,8] Relatedly, selective CAC testing can also identify low-risk individuals and help determine when deferring lipid-lowering therapy is appropriate [9]

The work of Luo and colleagues grants insight into the outcomes of risk conversations if SDM conversations were to end with classification alone. If perceived ASCVD risk informs willingness to accept statin therapy, as Luo and colleagues suggest, then it is essential that clinicians offer personalization and reclassification to ensure patients understand the true extent of their risk to make informed decisions. It is important to emphasize that many personalization approaches require only consistent use of a standardized focused history, i.e., inquiry into at-risk conditions, such as inflammatory diseases or adverse pregnancy outcomes. While a myriad of examples exist in medicine where standardized approaches can improve care delivery, [10,11] data are lacking but promising [12] for incorporating this standardization into ASCVD risk personalization and statin initiation.

Luo and colleagues also support a growing body of evidence linking improved health literacy to greater willingness to take statins [13] In a post hoc exploratory analysis, Luo and colleagues found that prior cholesterol education from a medical professional was associated with a lower SWD. While historically, use of pamphlets, videos, and visual graphics demonstrated improved patient knowledge and engagement and reduced risk of side effects, interactive tools, such as the Statin Choice Decision Aid (SCDA), may be useful, with observational data demonstrating an increase in statin prescriptions with SCDA use, though randomized data are limited [[14], [15], [16]].

The authors should be lauded for pursuing exploratory work that helps better understand patients’ views in one of the most common and complex clinical scenarios. Luo and colleagues grant a powerful glimpse into the numerous factors that influence patient decision-making and pose an opportunity for clinicians to reflect on how best to engage in SDM with patients. While this study focused on a 10-year risk horizon, the introduction of PREVENT-ASCVD 30-year risk scores and increased SDM among younger individuals remain areas for further exploration, including understanding how SWD may vary over time. Furthermore, this study used a virtual, simulated encounter, without the nuanced clinician-patient conversation focused on values and goals that underpin effective SDM. While this study is otherwise limited by its small sample size and the source of participants (i.e., those who opted in to surveys), these findings should not be readily dismissed.

Randomized studies should evaluate multiple strategies that may affect SWD–including integration of the CPR framework with standardized, inquiry-based risk-enhancing factor assessments–while collecting cost-benefit data for subsequent implementation. Guidelines should consider further development of toolkits grounded in communication science and psychological principles, with motivation rooted in patient perspectives and clinical evidence. To prioritize optimal and personalized SDM, clinicians should utilize the CPR framework to communicate risk, integrate patients’ prior experiences and values, and promote effective, evidence-based educational initiatives.

CRediT authorship contribution statement

Eve Manghis: Conceptualization, Writing – original draft, Writing – review & editing. Ramzi Dudum: Conceptualization, Writing – review & editing.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ramzi Dudum reports a relationship with Novartis Pharmaceuticals Corporation that includes: consulting or advisory. Ramzi Dudum reports a relationship with American Society of Preventive Cardiology that includes: board membership. Ramzi Dudum reports a relationship with Continuing Education Company that includes: speaking and lecture fees. Ramzi Dudum currently serves as an associate editor for this journal. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

  • 1.Writing Committee Members. Blumenthal R.S., Morris P.B., et al. ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17) doi: 10.1161/CIR.0000000000001423. [DOI] [PubMed] [Google Scholar]
  • 2.Lazar L.D., Pletcher M.J., Coxson P.G., Bibbins-Domingo K., Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124(2):146–153. doi: 10.1161/CIRCULATIONAHA.110.986349. [DOI] [PubMed] [Google Scholar]
  • 3.Chobufo M.D., Regner S.R., Zeb I., Lacoste J.L., Virani S.S., Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022;29(14):1830–1838. doi: 10.1093/eurjpc/zwac103. [DOI] [PubMed] [Google Scholar]
  • 4.Luo Y., Kawakami H., Funada S., et al. Measuring public preferences for statin therapy using the smallest worthwhile difference. JAMA Intern Med. 2026;186(4):488. doi: 10.1001/jamainternmed.2025.7958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Luo Y, Kawakami H, Funada S. Ozawa S, et al. Factors associated with patient preferences for statin therapy in primary prevention. Am J Prev Cardiol. 2026 doi: 10.1016/j.ajpc.2026.101776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brodney S., Valentine K.D., Sepucha K., Fowler F.J., Barry M.J. Patient preference distribution for use of Statin Therapy. JAMA Netw Open. 2021;4(3) doi: 10.1001/jamanetworkopen.2021.0661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gupta A., Lau E., Varshney R., et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10(8):833–842. doi: 10.1016/j.jcmg.2017.01.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nerlekar N., Vasanthakumar S.A., Whitmore K., et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial. JAMA. 2025;333(16):1403. doi: 10.1001/jama.2025.0584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.The role of coronary artery calcium in statin eligibility based on the American Heart Association’s PREVENT calculator: insights from MESA. J Am Coll Cardiol. 2026;88:739–748. doi: 10.1016/j.jacc.2026.05.039. https://www.jacc Accessed September 15. [DOI] [PubMed] [Google Scholar]
  • 10.Thomassen Ø, Storesund A., Søfteland E., Brattebø G. The effects of safety checklists in medicine: a systematic review: effects of safety checklists in medicine. Acta Anaesthesiol Scand. 2014;58(1):5–18. doi: 10.1111/aas.12207. [DOI] [PubMed] [Google Scholar]
  • 11.Pronovost P., Needham D., Berenholtz S., et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355(26):2725–2732. doi: 10.1056/NEJMoa061115. [DOI] [PubMed] [Google Scholar]
  • 12.Rashid S., Suero-Abreu G.A., Tysarowski M., et al. Increasing statin prescription rates to prevent cardiovascular disease among high-risk populations: a quality improvement intervention centred on a novel interactive tool. BMJ Open Qual. 2022;11(3) doi: 10.1136/bmjoq-2022-001947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sparrow R.T., Khan A.M., Ferreira-Legere L.E., et al. Effectiveness of interventions aimed at increasing statin-prescribing rates in primary cardiovascular disease prevention: a systematic review of randomized clinical trials. JAMA Cardiol. 2019;4(11):1160. doi: 10.1001/jamacardio.2019.3066. [DOI] [PubMed] [Google Scholar]
  • 14.Mann D.M., Ponieman D., Montori V.M., Arciniega J., McGinn T. The Statin Choice decision aid in primary care: a randomized trial. Patient Educ Couns. 2010;80(1):138–140. doi: 10.1016/j.pec.2009.10.008. [DOI] [PubMed] [Google Scholar]
  • 15.Martinez K.A., Montori V.M., Rodriguez F., et al. Association between exposure to statin choice and adherence to statins: an observational cohort study. Med Decis Mak Int J Soc Med Decis Mak. 2025;45(7):884–891. doi: 10.1177/0272989X251346508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Martinez K.A., Montori V.M., Rodriguez F., et al. Clinician use of the Statin Choice shared decision-making encounter tool in a major health system. J Gen Intern Med. 2024;39(9):1583–1589. doi: 10.1007/s11606-023-08597-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Preventive Cardiology are provided here courtesy of Elsevier

RESOURCES